Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00063141




Registration number
NCT00063141
Ethics application status
Date submitted
20/06/2003
Date registered
25/06/2003
Date last updated
12/04/2010

Titles & IDs
Public title
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Scientific title
Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma
Secondary ID [1] 0 0
CA225-006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - cetuximab
Treatment: Drugs - Irinotecan
Treatment: Drugs - Irinotecan

Experimental: Arm A -

Active Comparator: Arm B -


Treatment: Drugs: cetuximab
Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision

Treatment: Drugs: Irinotecan
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Treatment: Drugs: Irinotecan
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Every 3 months after subject off-treatment
Secondary outcome [1] 0 0
Progression Free Survival
Timepoint [1] 0 0
Q6 Weeks
Secondary outcome [2] 0 0
Response
Timepoint [2] 0 0
Q6 Weeks
Secondary outcome [3] 0 0
Duration of Response
Timepoint [3] 0 0
Q6 Weeks
Secondary outcome [4] 0 0
Time to Response
Timepoint [4] 0 0
Q6 Weeks
Secondary outcome [5] 0 0
Disease Control Rate
Timepoint [5] 0 0
Q6 Weeks
Secondary outcome [6] 0 0
Safety
Timepoint [6] 0 0
Q3 Weeks
Secondary outcome [7] 0 0
Quality of Life
Timepoint [7] 0 0
Q6 Weeks
Secondary outcome [8] 0 0
Health Economics
Timepoint [8] 0 0
Q3 Weeks

Eligibility
Key inclusion criteria
- Histologically documented colorectal cancer which is EGFR-positive by
immunohistochemistry [IHC] (may be based on archival samples) and is metastatic.

- Prior oxaliplatin administered for the first-line treatment of metastatic colorectal
cancer.

- Prior fluoropyrimidine-containing regimen (5-fluorouracil [5-FU], capecitabine, or
uracil/tegafur [UFT]), for the first-line treatment of metastatic disease.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- A serious uncontrolled medical disorder that, in the opinion of the Investigator,
would impair the ability of the subject to receive protocol therapy

- Unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease

- Known or documented brain metastases

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2007
Sample size
Target
Accrual to date
Final
1302
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA
Recruitment hospital [1] 0 0
ImClone Investigational Site - Perth
Recruitment hospital [2] 0 0
ImClone Investigational Site - Sydney
Recruitment hospital [3] 0 0
ImClone Investigational Site - Wollongong
Recruitment hospital [4] 0 0
ImClone Investigational Site - South Brisbane
Recruitment hospital [5] 0 0
ImClone Investigational Site - Adelaide
Recruitment hospital [6] 0 0
ImClone Investigational Site - Wien
Recruitment postcode(s) [1] 0 0
- Perth
Recruitment postcode(s) [2] 0 0
- Sydney
Recruitment postcode(s) [3] 0 0
- Wollongong
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment postcode(s) [5] 0 0
- Adelaide
Recruitment postcode(s) [6] 0 0
- Wien
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
North Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Utah
Country [31] 0 0
United States of America
State/province [31] 0 0
Virginia
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
United States of America
State/province [33] 0 0
Wisconsin
Country [34] 0 0
Austria
State/province [34] 0 0
Graz
Country [35] 0 0
Austria
State/province [35] 0 0
Salzburg
Country [36] 0 0
Austria
State/province [36] 0 0
Wein
Country [37] 0 0
Austria
State/province [37] 0 0
Wien
Country [38] 0 0
Belgium
State/province [38] 0 0
Charleroi
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Brno
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Olomouc
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Praha 5
Country [42] 0 0
Finland
State/province [42] 0 0
Helsinki
Country [43] 0 0
France
State/province [43] 0 0
Avignon
Country [44] 0 0
France
State/province [44] 0 0
Marseille
Country [45] 0 0
France
State/province [45] 0 0
Nice
Country [46] 0 0
France
State/province [46] 0 0
Saint Herblain
Country [47] 0 0
Germany
State/province [47] 0 0
Aschaffenburg
Country [48] 0 0
Germany
State/province [48] 0 0
Augsburg
Country [49] 0 0
Germany
State/province [49] 0 0
Dessau
Country [50] 0 0
Germany
State/province [50] 0 0
Dortmund
Country [51] 0 0
Germany
State/province [51] 0 0
Essen
Country [52] 0 0
Germany
State/province [52] 0 0
Hamburg
Country [53] 0 0
Germany
State/province [53] 0 0
Hanburg
Country [54] 0 0
Germany
State/province [54] 0 0
Kaiserslautern
Country [55] 0 0
Germany
State/province [55] 0 0
Kassel
Country [56] 0 0
Germany
State/province [56] 0 0
Magdeburg
Country [57] 0 0
Germany
State/province [57] 0 0
Mainz
Country [58] 0 0
Germany
State/province [58] 0 0
Mannheim
Country [59] 0 0
Germany
State/province [59] 0 0
Muchnhen
Country [60] 0 0
Germany
State/province [60] 0 0
Munchen
Country [61] 0 0
Germany
State/province [61] 0 0
Regensburg
Country [62] 0 0
Germany
State/province [62] 0 0
Saarbrucken
Country [63] 0 0
Germany
State/province [63] 0 0
Stralsund
Country [64] 0 0
Germany
State/province [64] 0 0
Stuttgart
Country [65] 0 0
Hong Kong
State/province [65] 0 0
Hong Kong
Country [66] 0 0
Italy
State/province [66] 0 0
Milano
Country [67] 0 0
Italy
State/province [67] 0 0
Ancona
Country [68] 0 0
Italy
State/province [68] 0 0
Bergamo
Country [69] 0 0
Italy
State/province [69] 0 0
Candiolo
Country [70] 0 0
Italy
State/province [70] 0 0
Firenze
Country [71] 0 0
Italy
State/province [71] 0 0
Genova
Country [72] 0 0
Italy
State/province [72] 0 0
Livomo
Country [73] 0 0
Italy
State/province [73] 0 0
Modena
Country [74] 0 0
Italy
State/province [74] 0 0
Napoli
Country [75] 0 0
Italy
State/province [75] 0 0
Perugia
Country [76] 0 0
Italy
State/province [76] 0 0
Reggio Emilia
Country [77] 0 0
Italy
State/province [77] 0 0
Roma
Country [78] 0 0
Italy
State/province [78] 0 0
Rome
Country [79] 0 0
Netherlands
State/province [79] 0 0
Apeldorn
Country [80] 0 0
Netherlands
State/province [80] 0 0
Dordrecht
Country [81] 0 0
Norway
State/province [81] 0 0
Oslo
Country [82] 0 0
Portugal
State/province [82] 0 0
Porto
Country [83] 0 0
Slovakia
State/province [83] 0 0
Bratislava
Country [84] 0 0
Sweden
State/province [84] 0 0
Lund
Country [85] 0 0
Sweden
State/province [85] 0 0
Stockholm
Country [86] 0 0
Switzerland
State/province [86] 0 0
Bern
Country [87] 0 0
Switzerland
State/province [87] 0 0
Liestal
Country [88] 0 0
Switzerland
State/province [88] 0 0
Zurich
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Aberdeenshire
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Avon
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Central
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Dorset
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Greater London
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Hampshire
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether overall survival is prolonged in subjects
with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated
with cetuximab in combination with irinotecan compared with irinotecan alone as second-line
therapy following treatment with a fluoropyrimidine and oxaliplatin based,
non-irinotecan-containing regimen.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00063141
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
E-mail: ClinicalTrials@ ImClone.com
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00063141